ortataxel
Sponsors
Theradex, Roswell Park Cancer Institute, Mario Negri Institute for Pharmacological Research
Conditions
GlioblastomaKidney CancerLung CancerLymphoma
Phase 2
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00039156
Start: 2002-01-31Updated: 2008-07-24
BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer
CompletedNCT00054314
Start: 2002-03-31Updated: 2022-09-26
BAY 59-8862 in Treating Patients With Advanced Kidney Cancer
NCT00039169
Start: 2001-12-31Updated: 2008-07-24
An Efficacy Study Of Ortataxel In Recurrent Glioblastoma
CompletedNCT01989884
Start: 2013-11-30End: 2016-12-31Updated: 2019-10-23